An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.
Columnist G Shellye Horowitz writes that postponing factor infusions may be tempting, but prophylaxis is better than a bleed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback